Nykredit A/S’s MoonLake Immunotherapeutics MLTX Stock Holding History

Nykredit A/S’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.63K	Buy	+289	New	+$5.24K	﹤0.01%	1912

Other funds holding MLTX

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Nykredit A/S's MLTX Position: Q2 2026 in Review

Nykredit A/S opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 289 shares worth $5.63K. The stake represents ﹤0.01% of the portfolio and ranks #1912 among its holdings.

84 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Nykredit A/S held 289 shares of MoonLake Immunotherapeutics worth $5.63K as of Q2 2026.
MoonLake Immunotherapeutics was a new Nykredit A/S position in Q2 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1912 holding.
84 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.